Skip to main content

Table 1 Individual clinical and immunohistochemical markers for the prediction of early versus late recurrence in transATAC

From: Markers for the identification of late breast cancer recurrence

  0-5 years 5-10 years
(number of all recurrences = 83) (number of all recurrences = 107)
  Univariate Multivariate Univariate Multivariate
  LR-χ2 LR-χ2a LR-χ2 LR-χ2a
(P value) (P value) (P value) (P value)
Nodal status (negative versus positive) 17.24 7.60 30.80 18.99
(<0.0001) (0.006) (<0.0001) (<0.0001)
Tumor size (≤2 versus >2 cm) 28.95 10.96 25.40 13.03
(<0.0001) (0.0009) (<0.0001) (0.0003)
Grade (well/moderate versus poor) 21.88 5.22 1.74 -
(<0.0001) (0.02) (0.2)
ER10 12.17 5.51 1.65 -
(0.004) (0.02) (0.2)
PgR10 18.81 6.46 1.45 -
(<0.0001) (0.01) (0.2)
Ki67 17.90 6.52 9.04 2.14
(<0.0001) (0.01) (0.003) (0.1)
HER2 (negative versus positive) 15.45 3.18 0.04 -
(<0.0001) (0.07) (0.8)
  1. aFor addition to model containing all other factors that were significant in the univariate model. ATAC, Arimidex, Tamoxifen, Alone or in Combination; ER, estrogen receptor; HER2, human epidermal growth factor; LR, likelihood ratio; PgR, progesterone receptor. Table was adapted from [9].